Short answer
Lexeo Therapeutics, Inc. (LXEO) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.02 (Unregistered Sales of Equity Securities). Mantle acquisition consideration: $5.3M cash plus $3.0M Lexeo shares, subject to closing adjustments.
Lexeo Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Mantle acquisition consideration: $5.3M cash plus $3.0M Lexeo shares, subject to closing adjustments
- Up to $1.0M additional cash contingent on specified events, creating potential future acquisition cost
- Up to $12.0M milestone payments over 12 years tied to development and regulatory achievements
- Milestone settlement split between cash and Lexeo shares, creating possible future dilution
- Milestones are uncertain, with no guaranteed payments or required resource commitment beyond commercially reasonable efforts
Item 3.02 · Unregistered Sales of Equity Securities
- Common Stock issued in the Merger, creating potential dilution for existing Lexeo shareholders
- Shares issued without Securities Act registration under Section 4(a)(2) and/or Regulation D exemptions
- Merger-related contingent consideration may require additional future equity issuance
- Equity issuance terms and share count are contained in Item 2.01, which investors should review for dilution impact
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lexeo Therapeutics, Inc. 8-K filings
Get the next LXEO 8-K as it lands
Follow LXEO for push alerts, or ask the research agent what this filing means.